INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,547,000 | -38.3% | 48,896 | -25.0% | 0.00% | 0.0% |
| Q2 2023 | $4,129,000 | +39.3% | 65,216 | +19.1% | 0.00% | 0.0% |
| Q1 2023 | $2,964,000 | +0.5% | 54,749 | -1.8% | 0.00% | 0.0% |
| Q4 2022 | $2,950,000 | +44.4% | 55,746 | +27.0% | 0.00% | 0.0% |
| Q3 2022 | $2,043,000 | +88.8% | 43,911 | +131.8% | 0.00% | – |
| Q2 2022 | $1,082,000 | -21.1% | 18,944 | -15.5% | 0.00% | – |
| Q1 2022 | $1,372,000 | -28.0% | 22,426 | -38.4% | 0.00% | – |
| Q4 2021 | $1,906,000 | +71.9% | 36,422 | +22.4% | 0.00% | – |
| Q3 2021 | $1,109,000 | +39.8% | 29,751 | +53.2% | 0.00% | – |
| Q2 2021 | $793,000 | +68.0% | 19,419 | +39.4% | 0.00% | – |
| Q1 2021 | $472,000 | -45.9% | 13,927 | -49.2% | 0.00% | – |
| Q4 2020 | $872,000 | +21.3% | 27,430 | -2.0% | 0.00% | – |
| Q3 2020 | $719,000 | +475.2% | 28,000 | +472.5% | 0.00% | – |
| Q2 2020 | $125,000 | +12.6% | 4,891 | -32.3% | 0.00% | – |
| Q1 2020 | $111,000 | -59.6% | 7,227 | -9.7% | 0.00% | – |
| Q4 2019 | $275,000 | +87.1% | 8,001 | -59.3% | 0.00% | – |
| Q3 2019 | $147,000 | -46.4% | 19,645 | -6.8% | 0.00% | – |
| Q2 2019 | $274,000 | -35.7% | 21,080 | -39.8% | 0.00% | – |
| Q1 2019 | $426,000 | +24.2% | 34,988 | +16.3% | 0.00% | – |
| Q4 2018 | $343,000 | -49.3% | 30,078 | -3.7% | 0.00% | – |
| Q3 2018 | $677,000 | +840.3% | 31,228 | +669.2% | 0.00% | – |
| Q2 2018 | $72,000 | -8.9% | 4,060 | +8.4% | 0.00% | – |
| Q1 2018 | $79,000 | +12.9% | 3,745 | -22.4% | 0.00% | – |
| Q4 2017 | $70,000 | -39.7% | 4,825 | -34.4% | 0.00% | – |
| Q3 2017 | $116,000 | +103.5% | 7,350 | +58.9% | 0.00% | – |
| Q2 2017 | $57,000 | -44.7% | 4,625 | -26.9% | 0.00% | – |
| Q1 2017 | $103,000 | -9.6% | 6,325 | -15.8% | 0.00% | – |
| Q4 2016 | $114,000 | +171.4% | 7,509 | +173.5% | 0.00% | – |
| Q3 2016 | $42,000 | -59.6% | 2,746 | +2.3% | 0.00% | – |
| Q2 2016 | $104,000 | +70.5% | 2,684 | +23.1% | 0.00% | – |
| Q1 2016 | $61,000 | -47.0% | 2,180 | +1.7% | 0.00% | – |
| Q4 2015 | $115,000 | +40.2% | 2,143 | +4.5% | 0.00% | – |
| Q3 2015 | $82,000 | -36.4% | 2,050 | -49.4% | 0.00% | – |
| Q2 2015 | $129,000 | +1333.3% | 4,050 | +1006.6% | 0.00% | – |
| Q1 2015 | $9,000 | – | 366 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |